Overshadowing as prevention of anticipatory nausea and vomiting

Overshadowing as prevention of anticipatory nausea and vomiting in pediatric cancer patients - a randomized placebo controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN30242271

Enrollment

Registered

2012-06-13

Start date

2013-06-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric oncology Cancer

Interventions

A randomized, double-blinded, placebo-controlled study in pediatric cancer patients treated with at least 3 chemotherapy cycles - Two arms: the experimental group will get salient candy and the contro

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. New diagnosis 2. German speaking 3. Age from 4 years 4. Receiving 3 chemotherapy cycles 5. Intervals of 7 days in-between the single chemotherapy cycles

Exclusion criteria

Exclusion criteria: 1. CNS or gastrointestinal tract cancer 2. Mental restrictions 3. Recurrent cancer 4. Prior radiotherapy

Design outcomes

Primary

Measure	Time frame
anticipatory nausea and vomiting (via patient administered discomfort logs)	—

Secondary

Measure	Time frame
1. Post-treatment nausea and vomiting (via patient administered discomfort logs) 2. Quality of life (via patient administered KINDL-R questionnaire), state-anxiety (via patient administered KAT-II, form P / STAI) and adherence (via ratings by medical personnel) 3. Relation between prevalence of post-treatment and anticipatory nausea and vomiting 4. Applicability of the overshadowing treatment in the hospital?s daily routine	—

Measure

Time frame

1. Post-treatment nausea and vomiting (via patient administered discomfort logs) 2. Quality of life (via patient administered KINDL-R questionnaire), state-anxiety (via patient administered KAT-II, form P / STAI) and adherence (via ratings by medical personnel) 3. Relation between prevalence of post-treatment and anticipatory nausea and vomiting 4. Applicability of the overshadowing treatment in the hospital?s daily routine

—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 23, 2026